Walmart stock is down nearly 8% in just 10 days—but is this a breakout or a trap? In this episode of Am I Catching a Falling Knife?, we dissect the bullish narrative around resilient sales growth and expose the margin pressures that could undermine it. Using real numbers, DCF models, and PEG ratios, we reveal why Walmart’s current price may be dangerously optimistic.📊 Topics Covered: • Walmart’s grocery & e-commerce boom • Margin squeeze from rising costs • DCF valuation vs market price • Buy levels to watch: $90, $80, $70⚠️ Not financial advice. Always do your own research.

Step into today’s Daily Market Narrative, where we decode the post‑Jackson Hole risk‑on frenzy without the financial jargon. 📉 Powell hints at rate cuts — markets cheer, SPY charts sparkle. 📈 Corporate earnings are up, consumer fears down… but is it all built on shaky Jenga blocks? Plus:Private credit default warnings 🚨Nvidia halts H20 chip production 🤖Tariff confusion freezes mail deliveries 📦Elon vs. Zuck in the AI chess match ♟️Brits feeling bullish on their wallets 💷US farmers caught between trade wars & bumper crops 🌾Whether you’re a bull, a bear, or just here for the drama, this is the market wrap you can’t miss. 🔔 Subscribe for daily satirical yet sharp market insights that keep you informed and entertained.

Is Palantir Technologies (PLTR) a misunderstood AI titan—or just another overhyped tech stock? In this episode of Am I Catching a Falling Knife?, Dave breaks down Palantir’s recent pullback, its ambitious AI platforms like Gotham, Foundry, and AIP, and the market’s growing skepticism around its valuation.We run a full DCF analysis, explore Wall Street’s shifting sentiment, and reveal our narrative-adjusted fair value of $16.08. Whether you're a retail investor or just curious about the future of AI in finance, this is a must-watch.🔔 Subscribe for more deep dives into tech stocks, AI trends, and market psychology.

Is Target (TGT) the ultimate bargain — or a dangerous value trap? In this episode of Am I Catching a Falling Knife?, we dissect the market narrative, Q2 2025 earnings miss, consumer spending trends, and the CEO transition shaking investor confidence.What you'll learn:Why discretionary spending weakness is hitting TGTThe real impact of operating leverage on earningsDCF valuation & fair price levels 📊 Disclaimer: This is for educational and entertainment purposes only. Not financial advice.#Target #TGT #StockAnalysis #Investing #StockMarketNews

Cisco Systems (CSCO) just took a 10% nosedive after its Q2 FY2025 earnings — but is this a falling knife or a hidden gem? In this episode of Am I Catching a Falling Knife?, we break down the revenue miss, margin compression, and future guidance to uncover whether Cisco is a value trap or a long-term buy.🔍 What you'll learn:Why Cisco stock dropped 10%Key financial metrics and valuation modelsDCF and multiples analysisBuy levels for knife-catchersPeer comparison: Arista & Juniper📊 Whether you're a long-term investor or a short-term trader, this deep dive will help you navigate the volatility and make smarter decisions.👉 Like, comment, and subscribe for more market breakdowns!Cisco stock crash 2025CSCO earnings Q2 FY2025Is Cisco a value trap?Cisco DCF valuationCisco vs Arista vs JuniperFalling knife investing strategyTech stock analysis 2025Cisco stock buy levelsCSCO forecast and price targetsCisco margin compression explained

Is AMAT a hidden gem or a dangerous trap? In this episode of Am I Catching a Falling Knife?, we break down the recent 10% plunge in Applied Materials stock and uncover the real story behind its cautious Q4 outlook. From China’s geopolitical headwinds to the AI-driven future of semiconductors, we analyze AMAT’s fundamentals, revenue breakdown, and valuation models to help you decide: is this the moment to buy?📉 Topics Covered:AMAT Q4 earnings impactSemiconductor demand trendsChina’s role in AMAT’s revenueDCF vs PEG valuation modelsCustom buy levels for investors⚠️ Not financial advice. Always do your own research.🔔 Subscribe for more deep dives into market movers and investing narratives.

Deere & Company (NYSE: DE) just dropped 22% after slashing its earnings outlook. Is this a golden buying opportunity or a dangerous trap? In this episode of Am I Catching a Falling Knife?, we break down the Q3 2025 earnings miss, margin compression, and cyclical headwinds hitting the ag giant. We analyze valuation, risks, and three key buy levels to watch. Don’t miss this deep dive into one of the market’s most iconic industrial stocks.👍 Like, Subscribe & Hit the Bell for more sharp market analysis.

Tapestry (TPR) just took a jaw‑dropping hit — plunging after weak earnings and slashed guidance. In this deep‑dive breakdown, we’ll uncover the hard‑hitting reasons behind the drop, from margin pressure and inventory build‑up to shifting consumer demand in key markets.Then we’ll put TPR under the microscope with a full financial statement review, discounted cash flow valuation, and peer comparison to names like Ralph Lauren and Capri Holdings. We’ll also share possible buy zones based on technicals and fundamentals — not financial advice — so you can see where the risk/reward might start to turn.If this breakdown helps, hit Like, Subscribe, and drop the next ticker you want analyzed in the comments.

CAVA just dropped ~10% after earnings on slowing same‑store sales and lowered guidance — despite beating on EPS and revenue. Is this a real opportunity or a classic falling knife? I break down the narrative, run a quick DCF vs PEG, and share my buy zones.What happened: EPS/rev beat, but growth narrative cracked on SSS slowdown and guidance trim.Numbers that matter: 398 stores, ~$954.3M TTM revenue, margin context, and why a 3% SSS delta can hit operating earnings double‑digits.Valuation check: DCF base vs narrative case ($56.89 → ~$47.22), PEG cross‑check (~$58.75), current price context (~$84.50).Buy levels I’m watching and what would change my mind.Risk lens: What could go right (traffic/mix/unit growth) vs wrong (promo intensity, cost creep, comp deceleration).This is not financial advice. Do your own research.Hashtags: #CAVA #CAVAStock #Earnings #StockMarket #Investing #DCF #RestaurantStocks

Cardinal Health (CAH) just dropped over 7% after Q4 FY2025 results and a $1.9B Solaris Health acquisition. Is this a falling knife… or a setup for a smarter entry? In this episode, we break down the revenue miss, thin 3.53% gross margins, financing risk, DCF and PEG valuations, and my buy levels based on a net −6.5% near-term earnings impact.Key points:EPS/guidance up, but revenue miss + deal financing weigh on near-term earnings.Thin gross margins amplify small revenue misses.Staggered buy levels for better margin of safety.If you found this useful, drop a like, comment your take on CAH’s Solaris deal, and subscribe for weekly “falling knife” breakdowns.#stocks #CAH #CardinalHealth #stockmarket #earnings #valuation #DCF #investing #healthcareDisclaimer: This video is for informational and entertainment purposes only and is not financial advice. Do your own research and consult a qualified advisor before investing.